Your browser doesn't support javascript.
loading
Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial.
Wapnir, Irene L; Gelber, Shari; Anderson, Stewart J; Mamounas, Eleftherios P; Robidoux, André; Martín, Miguel; Nortier, Johan W R; Geyer, Charles E; Paterson, Alexander H G; Láng, István; Price, Karen N; Coates, Alan S; Gelber, Richard D; Rastogi, Priya; Regan, Meredith M; Wolmark, Norman; Aebi, Stefan.
Afiliação
  • Wapnir IL; NRG Oncology, Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA. wapnir@stanford.edu.
  • Gelber S; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Frontier Science and Technology Research Foundation, Boston, MA, USA.
  • Anderson SJ; NRG Oncology and Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA.
  • Mamounas EP; NRG Oncology and University of Florida Health Cancer Center at Orlando Health, Orlando, FL, USA.
  • Robidoux A; NRG Oncology and Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada.
  • Martín M; GEICAM, Instituto de Investigacion SanitariaGregorio Marañon, Universidad Complutense, Madrid, Spain.
  • Nortier JW; BOOG, Dutch Breast Cancer Trialists' Group, Leids Universitair Medisch Centrum, Leiden, Netherlands.
  • Geyer CE; NRG Oncology and Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA.
  • Paterson AH; NRG Oncology and Tom Baker Cancer Centre, Calgary, Alberta, Canada.
  • Láng I; IBCSG and National Institute of Oncology, Budapest, Hungary.
  • Price KN; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Frontier Science and Technology Research Foundation, Boston, MA, USA.
  • Coates AS; IBCSG, Bern, Switzerland and University of Sydney, Sydney, Australia.
  • Gelber RD; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Harvard Medical School, and Frontier Science and Technology Research Foundation, Boston, MA, USA.
  • Rastogi P; NRG Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • Regan MM; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Wolmark N; NRG Oncology and the Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.
  • Aebi S; IBCSG, Luzerner Kantonsspital, Lucerne and University of Berne, Switzerland and Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.
Ann Surg Oncol ; 24(2): 398-406, 2017 Feb.
Article em En | MEDLINE | ID: mdl-27663567
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Mastectomia Segmentar / Protocolos de Quimioterapia Combinada Antineoplásica / Mastectomia / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Ann Surg Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Mastectomia Segmentar / Protocolos de Quimioterapia Combinada Antineoplásica / Mastectomia / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Ann Surg Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos